399 related articles for article (PubMed ID: 14586387)
1. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism.
Benowitz NL; Peng M; Jacob P
Clin Pharmacol Ther; 2003 Nov; 74(5):468-74. PubMed ID: 14586387
[TBL] [Abstract][Full Text] [Related]
2. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism.
Benowitz NL; Jacob P
Clin Pharmacol Ther; 2000 Jun; 67(6):653-9. PubMed ID: 10872647
[TBL] [Abstract][Full Text] [Related]
3. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
4. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.
Faber MS; Fuhr U
Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers.
Eap CB; Schnyder C; Besson J; Savary L; Buclin T
Clin Pharmacol Ther; 1998 Jul; 64(1):52-7. PubMed ID: 9695719
[TBL] [Abstract][Full Text] [Related]
6. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.
Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K
Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723
[TBL] [Abstract][Full Text] [Related]
7. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.
Poloyac SM; Tosheva RT; Gardner BM; Shedlofsky SI; Blouin RA
Clin Pharmacol Ther; 1999 Dec; 66(6):554-62. PubMed ID: 10613610
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
9. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
Denaro CP; Wilson M; Jacob P; Benowitz NL
Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
[TBL] [Abstract][Full Text] [Related]
10. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats.
Rockich K; Blouin R
Drug Metab Dispos; 1999 Sep; 27(9):1074-7. PubMed ID: 10460809
[TBL] [Abstract][Full Text] [Related]
11. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.
Hukkanen J; Jacob Iii P; Peng M; Dempsey D; Benowitz NL
Br J Clin Pharmacol; 2010 Feb; 69(2):152-9. PubMed ID: 20233178
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress.
Leclercq I; Desager JP; Horsmans Y
Clin Pharmacol Ther; 1998 Aug; 64(2):144-9. PubMed ID: 9728894
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity.
Dreisbach AW; Ferencz N; Hopkins NE; Fuentes MG; Rege AB; George WJ; Lertora JJ
Clin Pharmacol Ther; 1995 Nov; 58(5):498-505. PubMed ID: 7586943
[TBL] [Abstract][Full Text] [Related]
14. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment.
Lee AM; Yue J; Tyndale RF
Drug Metab Dispos; 2006 Sep; 34(9):1508-15. PubMed ID: 16763012
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cytochrome P4502E1 (CYP2E1) activity and hepatic and lymphocyte mRNA expression in patients with chronic hepatitis C.
Haufroid V; Ligocka D; Wallemacq P; Lison D; Horsmans Y
Toxicol Lett; 2005 Jan; 155(1):171-7. PubMed ID: 15585372
[TBL] [Abstract][Full Text] [Related]
17. Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta.
Czekaj P; Wiaderkiewicz A; Florek E; Wiaderkiewicz R
Arch Toxicol; 2005 Jan; 79(1):13-24. PubMed ID: 15448981
[TBL] [Abstract][Full Text] [Related]
18. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.
Khemawoot P; Yokogawa K; Shimada T; Miyamoto K
Biochem Pharmacol; 2007 Jan; 73(1):155-62. PubMed ID: 17049493
[TBL] [Abstract][Full Text] [Related]
19. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
[TBL] [Abstract][Full Text] [Related]
20. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
